Lanthanum Carbonate

Cipla USA, Inc. has initiated a Class II recall for Lanthanum Carbonate chewable tablets, 1000mg (lot NB240315), due to failed stability specifications, specifically an out-of-specification hardness test. This voluntary, nationwide recall impacts 1180 boxes, necessitating immediate action for procurement and supply chain teams to mitigate disruption and ensure patient safety within the US market.

Cipla USA, Inc. has initiated a Class II recall (D-0043-2025) for 1,875 boxes of Lanthanum Carbonate Chewable Tablets, 1000mg, distributed nationwide. The recall, stemming from complaints of crushed and broken tablets, highlights critical quality control vulnerabilities. This event demands immediate attention from procurement and supply chain leaders to assess inventory risks and ensure patient safety.